BRAF and cancer: previously demonstrated cellular movement/cancer/cellular response to therapeutics and cell death and survival/cell–cell signalling and interaction/cellular growth and proliferation as the key resistance pathways specific to BRAF resistance in A375 and SK‐MEL‐2 cell lines [35].